Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases

Chemical Biology and Drug Design

Volumn 74, Issue 6, 2009, Pages 527-534

  Forbes, Christopher ^a   Shi, Qicun ^a   Fisher, Jed F ^a   Lee, Mijoon ^a   Hesek, Dusan ^a   Llarrull, Leticia I ^a   Toth, Marta ^a   Gossing, Michael ^a   Fridman, Rafael ^b   Mobashery, Shahriar ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Latent thiolate; Thiirane; Tight binding inhibition; Zinc protease

Indexed keywords

2 [(4 PHENOXYPHENYLSULFONYL)METHYL]THIIRANE; GELATINASE; GELATINASE A; GELATINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG INHIBITION; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME MECHANISM; PRIORITY JOURNAL; RING OPENING;

CATALYTIC DOMAIN; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS, 1-RING; KINETICS; MATRIX METALLOPROTEINASE 2; MOLECULAR DYNAMICS SIMULATION; STEREOISOMERISM; SULFONES; ZINC;

EID: 70350073423     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2009.00881.x     Document Type: Article

References (51)

1. Helten H., Schirmeister T., Engels B. (2005) Theoretical studies about the influence of different ring substituents on the nucleophilic ring opening of three-membered heterocycles and possible implications for the mechanisms of cysteine protease inhibitors. J Org Chem 70 : 233 237.
2. Mladenovic M., Junold K., Fink R.F., Thiel W., Schirmeister T., Engels B. (2008) Atomistic insights into the inhibition of cysteine proteases: first QM/MM calculations clarifying the regiospecificity and the inhibition potency of epoxide- and aziridine-based inhibitors. J Phys Chem B 112 : 5458 5469.
3. Grabowsky S., Pfeuffer T., Morgenroth W., Paulmann C., Schirmeister T., Luger P. (2008) A comparative study on the experimentally derived electron densities of three protease inhibitor model compounds. Org Biomol Chem 6 : 2295 2307.
4. Ryu S.E., Choi H.J., Kim D.H. (1997) Stereochemistry in inactivation of carboxypeptidase A. Structural analysis of the inactivated carboxypeptidase A by an enantiomeric pair of 2-benzyl-3,4-epoxybutanoic acids. J Am Chem Soc 119 : 38 41.
5. Kim D.H., Mobashery S. (2001) Mechanism-based inhibition of zinc proteases. Curr Med Chem 8 : 959 965.
6. Lee M., Fridman R., Mobashery S. (2004) Extracellular proteases as targets for treatment of cancer metastases. Chem Soc Rev 33 : 401 409.
7. Brown S., Bernardo M.M., Li Z.H., Kotra L.P., Tanaka Y., Fridman R., Mobashery S. (2000) Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 122 : 6799 6800.
8. Rosenblum G., Meroueh S.O., Kleifeld O., Brown S., Singson S.P., Fridman R., Mobashery S., Sagi I. (2003) Structural basis for potent slow binding inhibition of human matrix metalloproteinase-2 (MMP-2). J Biol Chem 278 : 27009 27015.
9. Cross J.B., Vreven T., Meroueh S.O., Mobashery S., Schlegel H.B. (2005) Computational investigation of irreversible inactivation of the zinc-dependent protease carboxypeptidase A. J Phys Chem B 109 : 4761 4769.
10. Ikejiri M., Bernardo M.M., Meroueh S.O., Brown S., Chang M., Fridman R., Mobashery S. (2005) Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem 70 : 5709 5712. (Pubitemid 40980782)
11. Lee M., Bernardo M.M., Meroueh S.O., Brown S., Fridman R., Mobashery S. (2005) Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. Org Lett 7 : 4463 4465.
12. Lee M., Hesek D., Shi Q., Noll B.C., Fisher J.F., Chang M., Mobashery S. (2008) Conformational analyses of thiirane-based gelatinase inhibitors. Bioorg Med Chem Lett 18 : 3064 3067.
13. Ikejiri M., Bernardo M.M., Bonfil R.D., Toth M., Chang M.L., Fridman R., Mobashery S. (2005) Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem 280 : 33992 34002.
14. Aye M.M., Ma C., Lin H., Bower K.A., Wiggins R.C., Luo J. (2004) Ethanol-induced in vitro invasion of breast cancer cells: the contribution of MMP-2 by fibroblasts. Int J Cancer 112 : 738 746.
15. Ke Z., Lin H., Fan Z., Cai T.Q., Kaplan R.A., Ma C., Bower K.A., Shi X., Luo J. (2006) MMP-2 mediates ethanol-induced invasion of mammary epithelial cells over-expressing ErbB2. Int J Cancer 119 : 8 16.
16. Lin C.W., Shen S.C., Hou W.C., Yang L.Y., Chen Y.C. (2008) Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9. Mol Cancer Ther 7 : 1195 1206.
17. Hehr C.L., Hocking J.C., McFarlane S. (2005) MMP are required for retinal ganglion cell axon guidance at select decision points. Development 132 : 3371 3379.
18. Menon B., Singh M., Singh K. (2005) Matrix metalloproteinases mediate beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes. Am J Physiol Cell Physiol 289 : C168 C176.
19. Menon B., Singh M., Ross R.S., Johnson J.N., Singh K. (2006) beta-Adrenergic receptor-stimulated apoptosis in adult cardiac myocytes involves MMP-2-mediated disruption of beta1 integrin signaling and mitochondrial pathway. Am J Physiol Cell Physiol 290 : C254 C261.
20. Talamagas A.A., Efthimiopoulos S., Tsilibary E.C., Figueiredo-Pereira M.E., Tzinia A.K. (2007) Abeta(1-40)-induced secretion of MMP-9 results in sAPPalpha release by association with cell surface APP. Neurobiol Dis 28 : 304 315.
21. Kim D.H., Lilliehook C., Roides B., Chen Z., Chang M., Mobashery S., Goldman S.A. (2008) Testosterone-induced matrix metalloproteinase activation is a checkpoint for neuronal addition to the adult songbird brain. J Neurosci 28 : 208 216.
22. Gu Z., Cui J., Brown S., Fridman R., Mobashery S., Strongin A.Y., Lipton S.A. (2005) A highly specific inhibitor of MMP-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 25 : 6401 6408.
23. Wiesner C., Bonfil R.D., Dong Z., Yamamoto H., Nabha S.M., Meng H., Saliganan A., Sabbota A., Cher M.L. (2007) Heterogeneous activation of MMP-9 due to prostate cancer-bone interaction. Urology 69 : 795 799.
24. Martin M.D., Carter K.J., Jean-Philippe S.R., Chang M., Mobashery S., Thiolloy S., Lynch C.C., Matrisian L.M., Fingleton B. (2008) Effect of ablation or inhibition of stromal MMP-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 68 : 6251 6259.
25. Yu F., Kamada H., Niizuma K., Endo H., Chan P.H. (2008) Induction of MMP-9 expression and endothelial injury by oxidative stress after spinal cord injury. J Neurotrauma 25 : 184 195.
26. Kruger A., Arlt M.J., Gerg M., Kopitz C., Bernardo M.M., Chang M., Mobashery S., Fridman R. (2005) Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 65 : 3523 3526. (Pubitemid 40616323)
27. Sodek K.L., Ringuette M.J., Brown T.J. (2007) MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. Br J Cancer 97 : 358 367.
28. Kim D.H. (2004) Chemistry-based design of inhibitors for carboxypeptidase A. Curr Top Med Chem 4 : 1217 1226.
29. Kim D.H., Chung S.J. (1995) Inactivation of carboxypeptidase A by 2-benzyl-3,4-epithiobutanoic acid. Bioorg Med Chem Lett 5 : 1667 1672.
30. Sugimoto T., Kaiser E.T. (1978) Carboxypeptidase A catalyzed enolization of a ketonic substrate - new stereochemical probe for an enzyme-bound nucleophile. J Am Chem Soc 100 : 7750 7751.
31. Overall C.M., Kleifeld O. (2006) Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 94 : 941 946.
32. Sang Q.X., Jin Y., Newcomer R.G., Monroe S.C., Fang X., Hurst D.R., Lee S., Cao Q., Schwartz M.A. (2006) Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases. Curr Top Med Chem 6 : 289 316.
33. Klein T., P Geurink P., S Overkleeft H., K Kauffman H., Bischoff R. (2009) Functional proteomics on zinc-dependent metalloproteinases using inhibitor probes. ChemMedChem 4 : 164 170.
34. Shamamian P., Schwartz J.D., Pocock B.J., Monea S., Whiting D., Marcus S.G., Mignatti P. (2001) Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 189 : 197 206.
35. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. (2008) The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40 : 1362 1378.
36. Overall C.M., Butler G.S. (2007) Protease yoga: extreme flexibility of a matrix metalloproteinase. Structure 15 : 1159 1161.
37. Kotra L.P., Cross J.B., Shimura Y., Fridman R., Schlegel H.B., Mobashery S. (2001) Insight into the complex and dynamic process of activation of matrix metalloproteinases. J Am Chem Soc 123 : 3108 3113.
38. Rosenblum G., Meroueh S., Toth M., Fisher J.F., Fridman R., Mobashery S., Sagi I. (2007) Molecular structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase zymogen: challenging the cysteine switch dogma. J Am Chem Soc 129 : 13566 13574.
39. Rosenblum G., Van den Steen P.E., Cohen S.R., Grossmann J.G., Frenkel J., Sertchook R., Slack N., Strange R.W., Opdenakker G., Sagi I. (2007) Insights into the structure and domain flexibility of full-length pro-MMP-9/gelatinase B. Structure 15 : 1227 1236.
40. Okada Y., Morodomi T., Enghild J.J., Suzuki K., Yasui A., Nakanishi I., Salvesen G., Nagase H. (1990) MMP-2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem 194 : 721 730.
41. Piras P.P., Stirling C.J.M. (1987) Elimination and addition-reactions. Part 42. Structural effects on reactivity and mechanism in eliminative fission of 3-membered rings. J Chem Soc Perkin Trans 2 1265 1271.
42. Ogura K., Iihama T., Takahashi K., Iida H. (1984) Efficient preparation of 3-alkyl (or aryl)thio-1 (or 2)-propenyl p-tolyl sulfones. Bull Chem Soc Jpn 57 : 3347 3348.
43. Ogura K., Iihama T., Kiuchi S., Kajiki T., Koshikawa O., Takahashi K., Iida H. (1986) A facile allylic 1,3-rearrangement of a sulfonyl group and its application to a synthesis of alpha,beta-unsaturated ketones. J Org Chem 51 : 700 705.
44. Hirata T., Sasada Y., Ohtani T., Asada T., Kinoshita H., Senda H., Inomata K. (1992) Syn effect in the conversion of E-vinylic sulfones to the corresponding allylic sulfones. Bull Chem Soc Jpn 65 : 75 96.
45. Morrison J.F., Walsh C.T. (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Rel Areas Mol Biol 61 : 201 301.
46. Copeland R.A. (2005) Evaluation of Enzyme Inhibitors in Drug Discovery. A Guide for Medicinal Chemists and Pharmacologists. Wiley-Interscience : Hoboken, NJ.
47. Tao P., Fisher J.F., Mobashery S., Schlegel H.B. (2009) DFT studies of the ring-opening mechanism of SB-3CT, a potent inhibitor of matrix metalloproteinase 2. Org Lett 11 : 2559 2562.
48. Freskos J.N., Mischke B.V., DeCrescenzo G.A., Heintz R., Getman D.P., Howard S.C., Kishore N.N., McDonald J.J., Munie G.E., Rangwala S., Swearingen C.A., Voliva C., Welsch D.J. (1999) Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett 9 : 943 948.
49. Freskos J.N., McDonald J.J., Mischke B.V., Mullins P.B., Shieh H.S., Stegeman R.A., Stevens A.M. (1999) Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett 9 : 1757 1760.
50. Kleifeld O., Kotra L.P., Gervasi D.C., Brown S., Bernardo M.M., Fridman R., Mobashery S., Sagi I. (2001) X-ray absorption studies of human matrix MMP-2 bound to a highly selective mechanism-based inhibitor. Comparison with the latent and active forms of the enzyme. J Biol Chem 276 : 17125 17131.
51. Tochowicz A., Maskos K., Huber R., Oltenfreiter R., Dive V., Yiotakis A., Zanda M., Bode W., Goettig P. (2007) Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. J Mol Biol 371 : 989 1006.